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1. Introduction 
Traditional medicines occupy a central place among rural communities of developing 
countries for the provision of health care in the absence of an efficient public health care 
system (WHO, 2003).  
The use of traditional remedies is common in sub-Saharan Africa, and visits to traditional 
healers remain a mainstay of care for many people because of preference, affordability, and 
limited access to hospitals and modern health practitioners (Homsy et al., 1999). 
It is an important part of medical care in Uganda and throughout Africa, representing first 
line therapy for 70% of the population, (Homsy et al., 2004). For many, traditional herbal 
medicines may be the only source of treatment available. The main reasons to explain this 
are: traditional medicines are often more accessible compared with licensed drugs; there are 
no records attesting the resistance to whole-plant extracts possibly due to the synergistic 
action of their constituents; phytotherapy, possibly produces fewer adverse effect than 
chemotherapy (Willcox and Bodeker, 2000).  
In Africa more than 2,000 plants have been identified and use as herbal medicines. 
However, very few of these plants have been screened for safety in resource-constrained 
countries including Uganda. It is time to ask in a systematic and scientific manner how these 
local treatments work, what are the best means to establish their safety and can they be used 
as traditionally prepared? The source of antimalarial drugs such as artemisinin derivatives 
and quinolines currently in use today were isolated from medicinal plants. Renewed interest 
in traditional pharmacopoeias has meant that researchers are concerned not only with 
determining the scientific rationale for plants usage, but also with the discovering of novel 
compounds of pharmaceutical value for the treatment of malaria.  
Herbals are as old as human civilization and they have provided a complete storehouse of 
remedies to cure acute and chronic diseases. Numerous nutraceuticals are present in 
medicinal herbs as key components. Scientific evaluation of herbal products has been 
limited, yet herbal products are the most commonly consumed health care products. 
Because of known pharmacological effects and potential interaction of many of these 
compounds with therapeutic drugs, a history of herbal intake should be considered as part 
of routine medical history and should be evaluated before any change in prescription drugs 
and before medical procedures (Schwartz et al 2000) 
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At present, work conducted on traditional medicine in Africa has mainly concentrated on 
the collection, identification, and classification of herbal products for treatment of different 
ailments. However, research in the areas of safety and toxicology is lacking. 
Traditional medicines, like modern pharmaceuticals can do harm, but because humans have 
been using herbal drugs for long time, they are considered safe and non-toxic so the 
toxicological actions of these agents have been mostly ignored, even while the effectiveness 
is either already known or under study (O'Hara et al., 1998). Willcox (1999), carried out a 
clinical study on ‘AM’ (coded to protect the intellectual property right of the traditional 
healers), a popular antimalarial herb that has a long history of use among the people of 
south-western Uganda. In her result, 'AM' significantly reduced parasite count between day 
1 and day 7, patients showed symptomatic improvement, but 50% of them experienced 
some side effects including vomiting, nausea and stomach upset. These were partly 
attributed to malaria itself as well as to 'AM' ingestion (Willcox, 1999).  
If the origin of herbs’ toxicity is not identified, the adverse effects may be wrongly 
associated with other environmental exposures or some traditional belief. Failure to 
establish the true cause of exposure also means that the patient continues taking the toxic 
herb. Thus, the screening of traditional remedies for safety and toxicity is recommended to 
protect public health. On the other hand, several plants used in Uganda traditional medicine 
can cause damage to genetic material and therefore have potential to cause long-term 
damage in patients when administered as medicinal preparations (Steenkamp, 2005).  
1.1 The main groups of active principle or constituents obtained from medicinal herbs 
The therapeutic effects of plant species are determined by their constituents. These affect the 
condition and function of the various human body organs, clear up residual symptoms or 
destroy the cause of the disease in most cases infectious micro-organisms. They help 
increase the body’s resistance to disease, retard or delay the processes of natural aging or 
facilitate the adaptation of the organism to certain conditions (Forantisek, 2001). Over the 
centuries, man used medicinal plants even though he was unable to find a rational 
explanation for their effects. It was not until the 19th century and after the rapid 
development of organic chemistry and pharmacology, that man determined which active or 
group of principles are responsible for a given therapeutic effect. Knowledge of these 
substances frequently served as a model for the synthetic preparation of new medicines, 
enabling the drug to be modified and made more effective. It was soon discovered that a 
better therapeutic effect was often obtained by the particular combination of active principle 
naturally present in each plant that by a single, isolated substance. The most important 
constituents are the secondary metabolism in plants, which includes alkaloids, glycosides, 
essential oils, tannins and the bitter principles. Products of secondary metabolism of plants 
are responsible for the plants’ therapeutics effects. Of greater importance for the plants 
themselves of course are the products of primary metabolism which are necessary for the 
proper function of the basic life processes in plants. Primary metabolism products are also 
used by man. This group includes sugars, fatty oils, organic acids, vitamins and protein. 
These products of primary metabolism themselves may have no therapeutic effect but may 
possibly increase the efficiency of the therapeutically important principles (70) 
1.2 Vernonia amygdalina  
(Aseraceae), also called bitter leaf is a popular African vegetable that grows as a shrub or 
small tree indigenous to Central and East Africa including Uganda (Huffman et al, 1996). It 
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produces large mass of forage and is drought tolerant (Hutchioson and Dalziel, 1963), it is 2 
– 5 m with petiolate leaf of about 6 mm diameter and elliptic shape. The leaves are green 
with a characteristic odour and a bitter taste. No seeds are produced and the tree has 
therefore to be distributed through cutting. It is known locally as Omubirizi in south-
western Uganda and used traditionally for pain relief and malaria attack. Patients are 
instructed to soak the plant leave in hot water about (80oC). They should then drink half a 
glass (about 0.25l) two times daily for 4-7 days. Smaller doses are prescribed for children 
according to their weight.They are used as vegetable and stimulate the digestive system in 
some other countries in the continent. 
 This plant has ethnomedical use in treating veneral diseases, gastrointestinal problems and 
malaria (Kambizi et al, 2001; Huffman et al, 2003; Hamill et al, 1992). Furthermore, they are 
used as local medicine against leech, which are transmitting bilharzias. Free living 
chimpanzees eat the leaves, if they have attacked by parasites (Huffman, M.A. 2003). There 
are reports concerning the hypoglycaemic, antineoplastic antibacterial and antioxidant 
properties of the plant. (Akah et al, 1992; Izevbigie et al, 2004; Taiwo et al, 1999; Iwalewa et 
al, 2005). Despite the varied uses of the plant, there are no information on its analgesic 
properties and exact toxicology on sub-chronic exposure, although some reports describe its 
antiplasmodial effects (Abosi et al 2005; Masaba et al 2000; Tona et al, 2004; Wilcox et al, 
1999). Previous phytochemical reports have shown the presence of steroid, saponins, 
flavonoids.  
2. Methods 
2.1 Research design 
Ninety traditional healers were identified through community and healers association 
leaders. Once identified, study staff members approached the individuals to determine 
eligibility. Eligibility criteria included 30 years of age and older, recognition as a traditional 
healer by the local community council, and having established an active practice in the 
community. Three districts (Kanungu/Bwindi area, Bushenyi and Mbarara) south-western 
Uganda were identified. With consent a taxonomist samples of antimalarial herb were 
obtained for this research study. 
 To evaluate consistency, interviews were conducted by a person specially trained in 
interview administration and who is fluent in the language of the participants. 
The ethnographic interview included questions about common plant names, sources of 
products, method of preparation, purpose of use, quantity of herbs use and perceived 
benefit of herbs in ameliorating malaria symptoms and improving overall health. Ethical 
forms were used in order to assure them of the defense of their knowledge and intellectual 
property right was applied. Traditional healer’s name, age, gender, and ethnicity tribe, were 
asked. We relied on the knowledge of healers and the taxonomist to select the products of 
greatest importance. This enabled us target products that have a high likelihood of 
possessing significant pharmacological activity. 
A strategy was developed that respected the healers’ rights to maintain propriety of unique 
blends of herbal medicine. Also, a memorandum of understanding was developed that 
disclosed our study objective, which is to characterize the pharmacologic activity and to 
elucidate the toxicity of these remedies in order to determine any potential adverse effect. 
We emphasized that we were interested in general knowledge about the remedy and not in 
specific formulation, and that it was not our intention to use the knowledge gained from this 
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study for commercial profit. Rather we would report back to them in a workshop the 
remedy’s indication and contraindication after completion of the study. We requested that 
all parties sign the agreement and copies were kept in a secure file. The result of the study 
was used to determine the most common botanical/herbal products used by the healers to 
treat malaria. Among the herbal products, Vernonia amygdalina which appeared in 80% in 
the interview was chosen for studies.  
Fidelity level: The fidelity level (Fl) (Alexiades et al, 2000) among the healers from the same 
district was calculated according to the following formula:  
Fl (%) = (Np/N) × 100 
Np is the number of healers from one given district that claim a use of a plant species to 
treat a particular disease, and N is the number of healers from the same district that use the 
plants as a medicine to treat any given disease. The formula was applied in order to 
compare data from different district where the survey was performed. 
2.2 Extract preparation 
Leaves of V. amygdalina were collected from the botanical garden of the Rukararwe 
Traditional Medicine Health Center, a division of Rukararwe Partnership Workshop for 
Rural Development (RPWRD) in Bushenyi district. The plant was authenticated by Dominic 
Byarugaba, a botanist with the Department of Plant Biology, Mbarara University of Science 
and Technology (MUST), Uganda. A voucher specimen is kept in the department. The plant 
material was air-dried and grounded into a coarse powder. About (350g) of this powder 
were macerated in 2 L of distilled water for 24 h with occasional shaking (GFL 3017 
Germany) and then extracted using a soxhlet extractor (Gallemkamp, England). The 
resultant extract was evaporated in a water bath, under controlled temperature not 
exceeding the one used by the healers in their plant preparation (80oC) to yield a 32.3 g of 
semi solid residue.  
2.3 Animals 
Adult Wistar rats (130 – 150g) and Swiss albino mice (18 – 26g) of either sex, maintained at 
Animal Facility Centre were used for the acute toxicity and 14 days sub-chronic 
experiments. The animals were kept in plastic cages at room temperature and moisture, 
under a naturally illuminated environment of 12:12 h dark/light cycle. Animals were fed 
the standard diet and had access to tap water ad libitum.  
Male Wistar rats were used for the 6 week exposure studies.. At dosing, animals were 8 to 
12 weeks old. All animals were clinically monitored at the time of delivery and during 
acclimation period, and were maintained at the Animal Facility Centre. Animals found 
unsuitable were excluded from the experiment. Animals were housed in plastic cages under 
same conditions described above; they were fed with standard diet (Mice pallet), and had 
access to tap water ad libitum. The animal experiments were conducted according to the NIH 
Guide on Laboratory Animals for Biomedical Research (NIH, 1978) and ethical guidelines 
for investigation of experimental pain in conscious animals (Zimmermann et al, 1983). 
2.4 Antiplasmodial activity 
The test was conducted according to the curative procedure described earlier (Saidu et al, 
2000; Adzu et al, 2003). A donor mouse infected with rodent malaria (Plasmodium berghei) 
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was anaesthetized with chloroform and the abdomen opened. Blood was collected through 
cardiac puncture with a sterile needle and syringes in such a way that 0.2 ml of the blood 
containing about 1 x 107 infected red cells. Twenty-five mice were inoculated i.p. with 0.2 
mL each. The mice were then randomized and grouped into five (n = 5) and treated as 
follows on day 3 (D3). Group 1 received normal saline, group 2 received chloroquine (CQ, 
5mg/kg, i.p.); while groups 3-5 received (50, 100, and 200 mg/kg, i.p.). The treatment 
continued daily until day 7. Thick and thin blood smear were collected daily from tail blood, 
fixed with methanol, stained with 4% Giemsa at pH 7.2 for 45 min and examined 
microscopically (Nikon YS2-H Japan). The increase/decrease in parasitaemia, defined as the 
number of infected and uninfected red blood cell RBCs, were counted on five different 
fields, and mean survival time (within 30 days) was recorded. 
2.5 Evaluate the antinociceptive activity of the selected antimalarial 
2.5.1 Acetic acid-induced writhing in mice 
Analgesia was assessed according to the method of Siegmund et al. (1957), as was modified 
by Koster et al, 1959). The mice were divided into different groups (of five mice each). They 
were differently pre-treated with the extract (50, 100, 200mg/kg i.p), aspirin (100mg/kg i.p) 
and normal saline (10ml/kg i.p). 30, 60, 90 and 120min after the treatment, 0.7% 
acetylsalicylic acid (ASA) (Sigma Chemicals Co) 10ml/kg i.p was administered to the mice. 
They were placed in a transparent cage, 5mins after administration of acetic acid, the 
number of abdominal constrictions (writhes) made within 10min of every mouse was 
counted. The results of the treatment groups were compared with those of normal saline 
pre-treated control. The percentage of the writhes was calculated as (test mean/control 
mean)  100.  
2.5.2 Formalin test 
For the formalin studies, rats were injected with 0.05 ml of formalin (2.5% formaldehyde) 
into the sub-plantar surface of the left hind paw 30min after treatment with saline, extract or 
ASA. Severity of pain (for both control and test groups (n = 5)) were simultaneously 
observed and rated as scores using (Dubuisson et al, 1977) pain measurements. This was 
rated as follows: (0) rat can bear weight on injected paw; (1) light resting of the paw on floor; 
(2) partial elevation of the injected paw, and (3) total elevation, licking and biting of paw. 
These observation were recorded every minute for the first 10 min (early phase) and at 
every 5 min for the period between 15 and 60min (late phase). 
2.5.3 Tail-flick test 
This test as first described [28], and subsequently modified (Janssen et al, 1969; Asongalem 
et al 2004a) was used. Briefly, before treatment, the terminal (2 cm) of each rat tail was 
immersed in hot water contained in a 500ml beaker and maintained at 55 ± 1oC using a 
thermo-regulated hot plate (Ugo Basile, Socrel DS-35) and the time (in seconds) between the 
onset of stimulation and tail withdrawal was measured as the tail-flick latency. Twenty five 
rats that shows response within 0 – 4 s were selected and grouped into five (n = 5) for the 
study. Immediately after basal latency assessment, normal saline, reference drug (Pethidine 
hydrochloride; Bayer, England) or the plant extract were administered and the reaction time 
again recorded at 30 and 60min. after administration the extract. (50 – 200 mg/kg p.o) 
(Sanchez-Mateo et al, 2006). 
www.intechopen.com
 
Toxicity and Drug Testing 
 
172 
2.6 Acute and sub-chronic toxicity of the herbs 
2.6.1 Acute – toxicity test 
The intraperitoneal (i.p) acute toxicity of the extract was evaluated in Swiss albino mice 
using a slightly modified Lorke’s method (Lorke, 1998). Briefly, this method involved the 
determination of LD50 value in biphasic manner. The animals were starved of feed but 
allowed access to water 24 h prior to the study. In the initial investigatory step (phase 1), a 
range of doses of the extract producing the toxic effects was established. This was done by 
intraperitoneal administration of geometric doses of the extract (10, 100, 1000, 1500 mg/kg) 
to four groups of mice (n = 4). Based on the results obtained, a phase 2 investigatory step 
was done by giving more specific doses (200, 400, 600, 800 mg/kg i.p) to four other groups 
of mice. 
The mice were observed for 24 h for such behavioral signs as, excitement, dullness, ataxia or 
death. The LD50 was estimated from the geometric mean of the dose that caused 100% 
mortality and the dose which caused no lethality. 
The same procedure was used in rats which received (1000, 2000, 3000, 5000 mg/kg oral) in 
phase 1 and (1500, 3000, 4000, 5000 mg/kg oral) in the second phase.  
2.6.2 Two weeks sub-chronic toxicity test 
Twenty eight Wistar rats divided into four weight-matched groups, of seven rats each, (both 
sexes) were used for the study. Three test groups received 500, 1000, 2000 mg/kg V. 
amygdalina by gavage with biomedical needle (G 16, Length 76.2mm, diameter 3mm, 
Straight Harvard Apparatus) for 14 days. The control group received normal saline. 
Food and water intake were measured daily while the animal’s body weights were taken 
every other day. All animals were observed at least once daily for clinical signs (behavior 
such as lethargy, hyperactivity, depression and diarrhea). On day 14, immediately prior to 
euthanasia, all animals were anesthetized with chloroform and bled via the descending 
aorta for hematology and clinical chemistry determination. Organs were dissected and 
weighed to determine absolute and relative weight. The blood for clinical chemistry was 
allowed to clot in microtainer separator tubes, centrifuged and sera collected and stored at -
200C till ready for biochemical analyses. Commercial kits for Biosystem BTS-310, (Biosystem 
S.A Costa Brava 30, Barcelona, Spain) and Vitrous DT systems, Orthoclinical Diagnostics 
Johnson Company (US17) were used to analyze liver function, renal function and the 
electrolyte test. 
The hematological tests were carried out in an ethylene diamine tetra-acetic acid (EDTA) – 
anticoagulated blood. Hemoglobin (Hb) concentration was analysed by the 
cyanmethaemoglobin method, packed cell volume (PCV) by the micro-method, and white 
blood cell (WBC, total and differential) and platelet counts by visual methods Dacia et al, 
1991). The mean cell hemoglobin concentration (MCHC) was calculated by dividing Hb by 
PCV ( Dioka et al, 2002). 
2.6.3 Six weeks sub-chronic toxicity test 
For the six-week exposure studies, twenty eight male Wistar rats were divided into four 
weight-matched groups of seven rats each. Three of the four test groups received 750 1500, 
3000 mg/kg V. amygdalina by gavage with biomedical needle (G 16, Length 76.2mm, 
diameter 3mm, Straight Harvard Apparatus) consecutively for 43 days. The control group 
received distilled water vehicle only, via gavage. 
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Food and water intake were measured daily while the animal’s body weights were taken 
preexposure and weekly during exposure. All animals were observed at least once daily for 
clinical signs (behavior such as lethargy, hyperactivity, depression and diarrhea), and 
once/week clinical observations were performed on each rat by removing it from its cage 
and examining it for changes in general health. On day 44, immediately prior to euthanasia, 
all animals were anesthetized with chloroform and bled via the descending aorta for 
hematology and clinical chemistry determination. Organs were dissected and weighed to 
determine absolute and relative weight. The blood for clinical chemistry was allowed to clot 
in microtainer separator tubes, centrifuged and sera collected and stored at -70 0C until 
performing the biochemical analyses. The biochemical and hematological parameter were 
analyzed in the (New Italian Laboratory). Mbarara University of Science and Technology 
(MUST). 
The collected plasma samples were analyzed using a (HumanStar 180 and Humalyze 2000, 
Germany) autoanalyzer. Sixteen biochemical parameters were studied; plasma sodium, 
potassium and chloride were also assayed with (Humalyzer 17410, Germany) autoanalyzer 
with appropriate Human Kits. 
Hematological parameters were analyzed using (Beckman and Coulter, USA) with the 
appropriate kit (Coulter ACT 5 diff Diluent’s). 
3. Results 
In the study, a total of 90 healers from - sub-county from the three districts were 
interviewed. Most of them were members of traditional healers association in their district. 
Men dominate the practices of traditional medicine. 
Most of the traditional healers interviewed (81 out of 90), indicated to have passed through a 
several routes to become healers. All of the 81 were raised in families with traditional 
healers, who had involved them in the healing process and they were familiar with the 
profession. After some time they started to practice on their own. All reported on the 
importance of the family environment of a traditional healer in the context of acquiring 
knowledge and experience by members of the family. Furthermore it was reported that, the 
entrance into practice through these routes is facilitated through training by an experienced 
healer or a family member, who decides when the apprentice is ready to become an 
independent healer or to take up the practice. Eight out of 81 of the traditional healers 
indicated to have been instructed through dreams by their ancestral spirits to take up the 
traditional healing practice. They were required to learn and observe traditional healing 
procedures as dictated by the spirits. Indeed, the ancestral spirits are considered to be 
supernaturally powerful and ignoring them is to invite punishment to an individual and or 
her family. Of the 90 healers interviewed, two indicated to be self-taught healers. 
The leaves are the most frequently used plant part (56.3%), the root and fruits are used 
about 30% and 8.5% respectively, and the less used plant part is the bark (5.3%). The 
majority of the remedies are prepared in the form of decoction of fresh leaves. In our study 
area people do usually not store remedies for prolonged period of time. When needed they 
go out and collect the plant and prepare the remedy from fresh or sun dried material. 
Powders are prepared by pounding the fresh plant part or the crushed plant material after 
sun drying, 
Decoction is the most frequent method way of remedy preparation (65%) followed by 
infusion (13%), which is used for the powders; the maceration (11%) is mostly used for the 
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root preparation. Some remedies are prepared from a single plant species; however, in a few 
cases mixtures of plants or other substances are added as noted in Table 2 
Most of the remedies are taken orally and by external application as body bath, steam bath, 
and as ointment. Fumigation is mainly used in the treatment of headache and chest pain. 
For most of the remedies, the administered dose depends on the patient’s age, physical and 
health condition, and the duration of the illness. The doses vary from a teacup (70 ml) for 
adults to a handful (25 ml) for a child; a lack of agreement among the healers on doses of 
remedies was sometimes noted. The variation of the doses from one healer to another may 
show that the plants have a low degree of toxicity. For pharmacological investigation the 
active doses of these plants may not be high since they appear to treat the patients with low 
doses. The duration of treatment is not given for all remedies. According to the healers 
duration of treatment is difficult to determine and depends on how long the patient has 
been ill. The patient is supposed to take the remedy until healed. The only person able to 
determine the end of a treatment is the patient himself since the remedy is taken at home in 
the absence of the healers. 
The reported adverse effects for the use of these medicinal plants are vomiting and 
dizziness. According to the healers these effects are generally due to an overdose of the 
remedy. The adverse effects are generally moderate, and disappear at the end of the 
treatment. Also, patients are advice to drink a lot of milk, meat soup or porridge made from 
sorghum to help alleviate serious side effects. 
 
Districts Sub-County Numbers of healers Sex Age range 
   Males Females  
Kanungu  5 4 1 28–76 
  5 3 2 30–79 
  5 5 0 42–85 
  5 5 0 35–55 
  5 4 1 65–85 
Bushenyi kyangyenyi 5 5 0 47–70 
 Kigarama 5 5 0 38–80 
  5 5 1 27–70 
  5 5 0 49–104 
  5 5 0 56–80 
Mbarara Nyakayojo 10 8 2 45–73 
 Kinoni 10 10 0 55–62 
 Rugando 10 9 1 50–61 
 Bugamba 10 9 1 50-59 
Table 1. An overview of the traditional healers interviewed. 
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3.1 Acute toxicity test 
The median lethal dose LD50 was established to be 560  1.21 mg/kg i.p. in mice and 3.32  
0.15 g/kg oral in rats. Adverse signs of gaiting, reduction in stereotypic activities and deaths 
were however seen in high doses. 
3.2 Acetic acid-induced writhing in mice 
The aqueous extract of V. amygdalina (50, 100, 200mg/kg i.p) exhibited a significant (P<0.05) 
antinocicetive activity against acetic acid-induced writhing in mice. 50 and 100 mg/kg oral 
doses exhibited a dose-dependent anti-nociception that progressively reduced over a period 
of 90 min post-treatment. However, at 120min the reduced anti-nociceptive activity 
increases again at these doses. The dose of 200 mg/kg on the other hand caused a total anti-
nociception up to 120min. These results compared favorably with those of aspirin 
(100mg/kg i.p; Fig 1). 
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Fig. 1. Effect of aqueous extract of V.amygdalina leaves on acetic acid-induced writhing in 
mice for 5 min (NS, normal saline; Va, V. Amygdalina; ASA acetysalicylic acid). All data are 
presented as means ± S.E.M., n=5. The asterisk (*) denotes, significance (p<0.05) between 
treated group and NS control 
3.3 Formalin and tail-flick tests 
The extract at doses of 100 and 200 mg/kg induced significant (p<0.05) reduction in pain 
response in both phases (aphasic and tonic) of pain induced by formalin in comparison with 
control (Fig 2). 
In all cases ASA, a positive analgesic agent demonstrated significant anti-nociceptive action 
with a slightly stronger pharmacological intensity than V. amygdalina at 200 mg/kg in the 
late phase. The extract exerted no significant effect on nociception in tail-flick as values 
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obtained correspond with those with saline. However pethidine the reference agent 
markedly prolonged the tail-flick reaction time in rats (Fig 3) 
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Fig. 2. Effect of aqueous extract of V.amygdalina leaves on formalin test in rats (NT, non 
treated animals; Va, V. Amygdalina; ASA acetyl salicilic acid). All data are presented as 
means ± S.E.M., n=5. The asterisk (*) denotes significance (p<0.05) between treated group 
and NT control 
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Fig. 3. Effect of aqueous extract of V.amygdalina leaves on thermal stimulus-induced tail-flick 
test in rats (NS, normal saline; Va, V. Amygdalina; PH, penthidine hydrochloride). All data 
are presented as means ± S.E.M., n=5. The asterisk (*) denotes significance difference 
(p<0.05). 
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3.4 Antiplasmodial activity 
The extract caused a significant (P < 0.05) and dose-dependent reduction in mean 
parasitaemia in mice infected with Plasmodium berghei in comparison to CQ (5 mg/kg). 
The extract caused a parasitaemia reduction of 52% in 50 mg/kg, 64% and 73% in 100 and 
200 mg/kg respectively (Table 2). One animal death was recorded in the 200 mg/kg extract 
groups throughout the 30 days observation period of the experiment while the remaining 
mice recovered fully. All mice in the saline group were lost within 15 days of the study. 
 
 
Values are mean count S.E.M. (for n = 5) 
*Significantly (p<0.05) different from saline control group 
N.S., Normal saline 
Table 2. Curative activity of the aqueous extract of V. amygdalina and CQ against Plasmodium 
berghei in mice. 
3.5 Sub-chronic toxicity (14 days exposure) 
No treatment deaths occurred and no treatment related clinical signs were noted during the 
study. The extract did not exert significant changes on mean body and organ weight, fluid 
and food intake (Table 3). All animals demonstrated a progressive increase in body weight 
during the exposure. The organ weights were expressed as a percentage of the body weight 
(% relative organ weight), rather than as absolute weights, so as to take into consideration 
differences in the organ weight that may solely be attributable to differences in the body 
weights of the respective rats. The hematology result showed a significant decrease (p<0.05) 
in red blood count at the dose of 2000mg/kg compared to control (Table 4). The result of the 
clinical chemistry parameter showed a dose-dependent increase in direct and total bilirubin, 
there was also an increase in uric acid at the doses of 500 and 1000mg/kg compared to 
control (Table 5). 
3.6 Six weeks exposure 
Clinical observation, Body and organ weight  
At the end of the 43-day-period of drug administration, No overt signs of toxicity were seen 
in any of the animals during the course of the study. No statistical difference was observed 
between the body and organ weight of the control group and the assay group in the male 
rats receiving the three doses, all animals exhibited a gain in body weight. Organ weights (% 
relative organ weights) were similar to those of the corresponding organs from the control. 
(Fig 5 and 6).  
www.intechopen.com
 
Toxicity and Drug Testing 
 
178 
 
Values are expressed as mean  S.E.M. for n = 7 
Relative organs weight = Absolute Organ Weight X 100 
Final Organ Weight 
Table 3. Effect of V. Amygdalina on daily food and fluid intake, body weights and organs 
weight of rats. (14days exposure) 
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Parameter Control 500mg/kg 1000mg/kg 2000mg/kg 
Hb (g/dl) 12.17± 0.27 9.97± 0.73 11.88± 0.78 10.54±0.47 
PCV (%) 36.14±0.79 29.71±2.20 35.42± 2.34 31.42± 1.41 
MCHC (g/dl) 32.14±0.34 30.28±0.60 32.00±0.65 30.85±0.40 
RBC (x 1012/L) 4.64±0.13 3.84±0.25# 4.30±0.35# 3.58±0.14# 
Platelet (x 109) 156.42±3.77 139.85±4.38 153.28±6.95 136.71±3.82# 
WBS (x 109/L) 6.57±0.43 5.57±0.87 6.68±0.51 3.47±0.89# 
Neutrophil (%) 20.57±2.42 25.57±1.95* 24.00±1.77* 21.00±1.67 
Lymphocyte (%) 79.28±2.53 74.42±1.95 77.4±2.47 83.28±3.48* 
Values are expressed as means ± S.E.M for n = 7 
* Significantly increased (P0.05) compared to control. 
# Significantly reduced (P0.05) compared to control. 
Table 4. Effect of V. amygdalina on selected hematological parameter in rats (14days 
Exposure) 
 
Parameters Control 500 mg/kg 1000 mg/kg 2000 mg/kg 
AKL.Phos (iu/L) 212.1±2.21 215.5±3.77 218.8±8.11 218.7±3.45 
Total Protein (g/L) 71.5± 1.11 74.3±2.69 77.0± 0.54 73.7± 2.21 
Albumin (g/L) 38.3± 1.25 39.7± 1.04 40.0± 0.94 39.6± 0.76 
Direct Biliru (Mol/L) 1.8± 0.82 2.5± 1.01* 3.2± 1.51* 4.0± 1.78* 
Total Biliru (Mol/L) 4.2±2.65 6.28±2.63* 5.71±2.53* 6.57± 3.19* 
ALT (iu/L) 32.7±5.80 34.60±10.18 35.10±11.04 33.70± 6.23 
AST (iu/L) 42.28±10.27 40.43±10.68 41.29±12.32 41.14± 5.52 
Chol (Mol/L) 1.23±0.32 0.92±0.33 1.25±0.34 1.10± 0.28 
Trig (Mol/L) 0.51±0.04 0.86± 0.18 0.60±0.60 0.47± 0.06 
HDL (iu/l) 0.44±0.39 0.44± 0.31 0.36±0.07 0.42± 0.44 
LDL (Mol/L) 0.37±0.20 0.53± 0.19 0.69±0.20 0.64± 0.16 
VLDL (Mol/L) 0.23±0.02 0.39±0.08 0.27±0.02 0.21± 0.03 
CHO/HDL (Mol/L) 2.80±0.84 1.95±0.73 2.60±0.69 2.72± 0.80 
K+ (mMol/L) 6.92±028 8.04±0.50 7.02±0.52 7.35± 0.48 
Na+ (mMol/L) 139.14± 3.34 140.71± 5.84 147.43 ±2.79* 145.57 ± 1.06* 
Cl¯ (mMol/L) 107.57 ± 2.72 110.70 ± 5.32 117.40 ±4.37* 114.00 ± 1.46* 
HCO2¯ (mMol/L) 23.71±0.91 22.28±1.32 21.14±0.39 21.14± 0.40 
Uric Acid (Mol/L) 106.6± 6.74 164.6± 19.18 168.6±8.21 134.8±9.50 
Urea (mMol/L) 6.80±0.44 7.31±0.39 6.82±0.72 4.60± 0.41# 
Creat (mMol/L) 76.57±2.80 73.71± 8.4 70.14±2.52 76.85± 4.06 
Values are expressed as means ± S.E.M. for n = 7 
* Significantly increased (P0.05) compared to control. 
# Significantly reduced (P0.05) compared to control. 
ALT, Alanin Amino transferase 
AST. Aspartate amino transferase 
ALK. Phos, Alkaline Phosphatase. 
Table 5. Effects of V.Amygdalina on Clinical Chemistry Parameter in rats. (14days exposure) 
www.intechopen.com
 
Toxicity and Drug Testing 
 
180 
W
ei
g
h
t 
(g
)
Weeks
 Control
  750mg/kg
 1500mg/kg
 3000mg/kg
 
Fig. 5. Evolution of the mean ±SE of rat body weight during the subchronic toxicity of 
Vernonia amygdalina extract. 
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Fig. 6. Plots of the mean SE. Of the harvested organ weights during the sub-chronic toxicity 
study of V.amygdalina extract. 
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Doses 
mg/kg 
WBC 
(10
9
/ l) 
RBC 
(10
12
/l) 
HGB 
(g/dl) 
HCT 
(%) 
MCV 
(fL) 
MCH 
(pg) 
MCHC 
(g/dl) 
PLT 
(10
9
//) 
M
Control 4.80.8 8.41.2 16.92 446 534 202 382 42950 6.7  
750mg/kg 6.61.0 8.71.1 17.23 451 524 191 384 46418 6.5  
1500mg/kg 8.00.7* 8.20.6 16.71 433 532 200.3 383 55543 6.5  
3000mg/kg 8.50.3* 8.40.2 17.10.2 448 523 200.3 383 436161 6.7  
 
Values presented as mean  standard deviation. 
n = 7 
WBC = White blood cell; RBC = Red blood cell; HGB = Hemoglobin; HCT = Hematocrit; MCV = Mean corpus
corpuscular hemoglobin; MCHC = Mean corpuscular hemoglobin concentration; PLT = Platelets; NE = Neutrophi
Statistical analysis: ANOVA, then Dunnett’s test 
*Mean value of group is significantly different from control at p<0.05 
w
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Dose 
Mg/kg/d 
ASAT 
(U/L) 
ALAT 
(U/L) 
ALB 
(g/dl) 
TRIG 
(mg/dl) 
UREA 
(mg/dl)
CALC 
(mg/dl)
T.PROT
(g/L) 
PHOS 
(mg/dl)
CREAT 
(mg/dl) 
T.BIL 
(mg/dl)
URICAC
(mol/l) 
D.BIL 
(mg/dl)
T.CHO 
(mg/dl)
HDL 
mg/dl) 
LDL 
(mg/dl)
K 
(mmol/l)
NA 
(mmol
Control 132 
26 
93 
4 
3.4 
0.1 
120 
15 
52 
3 
12 
3 
33 
10 
24 
6 
0.5 
0.3 
0.38 
0.1 
80 
30 
0.20 
.02 
88 
10 
4.1 
0.7 
68 
9 
5.9 
0.2 
152 
3 
750 202 
29 
94 
9 
3.5 
0.2 
115 
13 
56 
2 
14 
4 
39 
15 
40 
11 
0.6 
0.2 
0.42 
0.1 
81 
40 
0.12 
.03 
69 
10 
3.4 
0.5 
55 
7 
5.7 
0.3 
146 
5 
1500 373* 
77 
186* 
26 
3.7 
0.2 
112 
17 
56 
3 
6.4 
1.8 
24 
5 
28 
5.9 
0.6 
0.2 
0.80 
0.2 
70 
25 
0.18 
.02 
83 
19 
6.7* 
0.7 
59 
15 
5.9 
0.4 
147 
4 
3000 313 
63 
140 
23 
3.3 
0.1 
104 
15 
57 
3 
3.9 
1.2 
24 
4 
16 
3.0 
0.5 
0.02 
0.58 
0.1 
148 
19 
0.10 
.02 
76 
7 
4.8 
0.6 
56 
6 
5.9 
0.4 
151 
2.4 
 
n = 7, Values presented as mean  standard deviation 
ASAT = Aspartate aminotransferase; ALAT = Alanine aminotransferase; ALB = Albumin; TRIG = Triglyceride; CAL = Calcium; T.PROT
Total protein; PHOS = Phosphate; CREAT = Creatine; T. BILI = Total bilirubin ; D. BILI = Direct bilirubin; T.CHO = Total Cholesterol; H
= High density lipoprotein; LDL = Low density lipoprotein; K = Potassium; NA = Sodium; AMY = Amylase  
Statistcal analysis: ANOVA, Dunnett’s test 
*Mean values of groups is significantly different from control at p<0.05.    
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4. Discussion 
As herbal medicine become more popular especially in rural areas, pharmacological 
evidences to understand the action of these medicine and the underlying mechanisms, to 
support the proper and safe use of these medicine are indispensable 
Our ethnopharmacology survey showed that medicinal plants are still widely used by the 
population in the area where the study was conducted. Several types of preparations of 
plants were used. The plants grow over an extended area and are used by healers separated 
by long distances. 
In the current study, the analgesic effect of the leave extract of Vernonia amygdalina was 
assessed using three nociceptive animal models. In the writhing response model, acetic acid 
is injected into the peritoneal cavity of mice. The acid causes nociception in the abdomen 
due to the release of various substances that excite pain nerve ending (Raj, 1996). According 
to previous reports this assay is commonly used in mice to detect both central and 
peripheral analgesic efficacy of agents (Dewey, 1970; Fukawa et al 1980), V amygdalina 
showed an ability to diminish the numbers of the writhing episode in a dose-dependent 
manner. The results of the writhing test alone did not ascertain whether antinociceptive 
effects are central or peripheral.  
The formalin test is considered a model for chronic pain (Duduisson and Dennis, 1977). In 
this test, animals present two distinct nociceptive behavior phases, which probably involve 
different stimuli. The first phase initiates immediately after formalin injection and lasts 3 to 
5 mins, resulting from chemical stimulations of nociceptor. The second phase initiates 15 to 
20 mins after formalin injection, lasts 20 to 40 mins and seems to depend on a peripheral 
mechanism as well as a central one. While substance P and bradykinins are involved in the 
first phase, histamine, 5HT, prostaglandins and bradykinin are involved in the second 
phase. The effect of extract was significant in both phases. Since the mechanism of the 
analgesic effect of V. amygdalina is apparent in these two models, it can however be 
speculated that this effect may be linked to processes in the prevention of sensitization of the 
nociceptor, down-regulation of the sensitized nociceptor and/or blockade of the nociceptor 
at peripheral and/or central levels.(Ferreira, 1990). Another possible mechanism may be 
that the extract blocks effect or the release of endogenous substances, including 
prostaglandin E2 (PGE2) and PGF2 that excites pain nerve ending which is found in writhing 
response test model of mice (Deraedt, et al, 1980).  
The extract fails to exhibit antinociceptive effect in the tail-flick test, as values obtain were 
not significantly different from control animals. Pethidine (50mg/kg p.o.) the reference drug 
used exhibited significant antinociceptive effect in rats. It is known that the tail-flick 
(thermal nociceptive) response appears to be a spinal reflex sensitive to opioid -agonists 
and non-thermal tests to opioid -agonists (Abbott, 1988; Furst et al, 1988), furthermore 
thermally-induced pain is also mediated by A and C fibers. The data in the present study 
suggest the involvement of  opioid receptors in the analgesic activity and a decrease 
activity of A and C fibers against inflammatory-induced activation but not thermally-
induced activation (Puig and Sorkin, 1980). 
Aqueous extracts of V. amygdalina were found to have in vivo activities against P. berghei in 
mice. At 200 mg/kg the antiplasmodial activity were comparable to CQ treated mice. 
Empirically, this plant is used in decoction alone, other plants may be added to reduce the 
side effect of nausea that result from the herb’s bitter taste (15).  
The acute oral toxicity results from the V. amygdalina extract (3.32  0.15 g/kg p.o) indicate 
that the extract may be safe based on the chemical labeling and classification of acute 
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systemic toxicity on oral LD50 values, recommended by the organization for Economic 
Cooperation and Development (Walum et al,1986). It has, however, been reported, that the 
median lethal dose is not an absolute value but is an inherently variable biologic parameter 
that cannot be compared to constants such as molecular weight or melting point (Oliver, 
1986). The adverse signs of gaiting, reduction in stereotypic activities and deaths were 
however seen in high doses. 
 In the sub-chronic study, the hematologic parameter shows a decrease in the RBC counts 
and an increased neutrophil in the treated groups. The serum chemistry parameter shows 
an increase in the direct and total bilirubin value. In several organs, mainly heart and liver, 
cell damage is followed by increased levels of a number of cytoplasmic enzymes in the 
blood, a phenomenon that provides the basis for clinical diagnosis of heart and liver 
diseases . For example, liver enzymes are usually raised in acute hepatotoxicity but tend to 
decreased with prolonged intoxication due to damage to the liver cells (Orisakwe et al, 
2004). In this study, the extract did not exert significant effects on the serum chemistry 
parameters, the increased in bilirubin levels were probably due to the decrease RBC values.  
 Since the traditional healers reported use of the drug as prophylactics against malaria, male 
rats were exposed to the extract for 6 weeks. No extract-related deaths occurred, the clinical 
condition of the animals, body weight gain, and food consumption were unaffected. Clinical 
pathology parameters (hematology, serum chemistry) exhibited no treatment-related effect. 
Organ weight changes can be sensitive indicators of target organ toxicity, and significant 
changes in organ weights may occur in the absence in changes in other pathology 
parameters (Bailey,S.A., 2004 ), for example, increased liver weight associated with hepatic 
cytochrome P450 induction is a common finding in toxicology studies. Liver weight 
increases of up to 20% relative to control without microscopic evidence of hepatocellular 
hypertrophy or changes in serum chemistries (Amacher, et al., 2000). Similarly modest dose-
related changes in kidney weight commonly occur in toxicology studies without 
histopathologic evidence of cellular alteration (Greaves, P. 2000).  
In conclusion, the results of this study showed analgesic activity of the extract with clear 
and significant antiplasmodial effects in mice, no indication of toxicity in rats, incidental 
findings below or above standard reference levels were all within control values based on 
historical reference ranges. This might explain the pharmacological basis for the successes in 
pain and malaria treatment claimed by traditional healers who use V. amygdalina.  
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